Shield Therapeutics plc (STX.L)

1.3500 +0.1250 (+10.20%) At close: 05:06PM BST

Shield Therapeutics plc

Northern Design Centre
Baltic Business Quarter
Gateshead NE8 3DF
United Kingdom
44 1915 118 500
https://www.shieldtherapeutics.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 27

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Gregory P. Madison	CEO & Executive Director	678k	N/A	1967
Dr. Christian Schweiger M.D., Ph.D.	Co-Founder & Non Executive Director	45k	N/A	1966
Mr. Santosh Shanbhag	Chief Financial Officer	N/A	N/A	1978
Ms. Lucy Kate Huntington-Bailey	General Counsel & Company Secretary	N/A	N/A	N/A
Ms. Suzanne Wood	Group HR Director	N/A	N/A	N/A
Ms. Carol Akinola	Head of Pharmacovigilance & Medical Information	N/A	N/A	N/A
Mr. Andrew Hurley	Chief Commercial Officer	N/A	N/A	1969
Kate Armanetti	Senior Director of People & Culture	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

Corporate governance

Shield Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.